Darbà, JosepKaskens, LisetteSorio Vilela, FrancescLothgren, Mickael2016-04-052016-04-052015-021178-6981https://hdl.handle.net/2445/96961The objective of this study was to estimate the cost-effectiveness of denosumab for fracture prevention compared with no treatment, generic bisphosphonates, and strontium ranelate in a cohort of osteoporotic postmenopausal women in Spain.13 p.application/pdfengcc-by-nc (c) Darbà, Josep et al., 2015http://creativecommons.org/licenses/by-nc/3.0/esAnàlisi cost-beneficiMenopausaOsteoporosiCost effectivenessMenopauseOsteoporosisCost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spaininfo:eu-repo/semantics/article6499142016-04-05info:eu-repo/semantics/openAccess25709480